Calcium Interactions with Cx26 Hemmichannel: Spatial Association between MD Simulations Biding Sites and Variant Pathogenicity

Juan M. R. Albano#a,b, Nahuel Mussini#a,b, Roxana Toriano,c,d Julio C. Facelli§*, Marta B. Ferraroa,b, and Mónica Pickholza,b

aFacultad de Ciencias Exactas y Naturales, Departamento de Física, Universidad de Buenos Aires, Argentina

bCONICET- Universidad de Buenos Aires, IFIBA, Buenos Aires, Argentina

cFacultad de Medicina, Departamento de Ciencias Fisiológicas, Laboratorio de Biomembranas, Buenos Aires, Argentina

dCONICET - Universidad de Buenos Aires, IFIBIO Houssay, Buenos Aires, Argentina

eDepartment of Biomedical Informatics, The University of Utah, 421 Wakara Way, Suite 140, Salt Lake City, Utah 84108, US.

# These authors contributed equally to this work.

Abstract

Connexinopathies are a collective of diseases related to connexin channels and hemichannels. In particular many Cx26 alterations are strongly associated to human deafness. Calcium plays an important role on this structures regulation. Here, using calcium as a probe, extensive atomistic Molecular Dynamics simulations were performed on the Cx26 hemichannel embedded in a lipid bilayer. Exploring different initial conditions and calcium concentration, simulation reached ~4 μs. Several analysis were carried out in order to reveal the calcium distribution and localization, such as electron density profiles, density maps and distance time evolution, which is directly associated to the interaction energy. Specific amino acid interactions with calcium and their stability were capture within this context. Few of these sites such as, GLU42, GLU47, GLY45 and ASP50, were already suggested in the literature. Besides, we identified novel calcium biding sites: ASP2, ASP117, ASP159, GLU114, GLU119, GLU120 and VAL226. To the best of our knowledge, this is the first time that these sites are reported within this context. Furthermore, since various pathologies involving the Cx26 hemichannel are associated with pathogenic variants in the corresponding CJB2 gene, using ClinVar, we were able to spatially associate the 3D positions of the identified calcium binding sites within the framework of this work with reported pathogenic
variants in the CJB2 gene. This study presents a first step on finding associations between molecular features and pathological variants of the Cx26 hemichannel.

**Graphical abstract**

![Graphical abstract](image)

**Keywords**

CONNEXIN; MOLECULAR DYNAMICS; POPC; VARIANT ANNOTATION

**Introduction**

Multicellular organisms require multiple types of inter-cellular communication in order to respond in an organized way - in either tissue or organ - to stimuli of the organism itself or from the environment that surrounds it [1–5]. The most common and ubiquitous form of this intercellular communication in animal tissues is through the Gap Junction Channels (GJCs) [2–4, 6, 7]. GJCs (Fig. 1) are structures that connect cells allowing the direct exchange of ions and molecules with a molecular weight cut-off of about 1kDa [8]. GJCs are involved in many cellular processes determining the normal physiology of an organism, such as cell proliferation, differentiation, migration, and apoptosis [2, 7–10]. Multiple pathologies and developmental disorders, such as hearing loss, skin diseases, peripheral and central neuropathic disorders, lens cataracts (Cx26, Cx30) and cardiac arrhythmias (Cx40), have been associated with different dysfunctions of hemichannels and GJCs [11–13]. Many of these pathologies are associated to specific genetic variants that change the Cx amino acid sequence [11, 12]. For example, two clinical phenotypes were associated to hearing loss due to Cx26 hemichannel malfunction [14] and a heterozygous missense mutation was identified in a family with dominant deaf-mutism and palmoplantar keratoderma [15].

The GJCs are constituted by the head-to-head non-covalent coupling of two hexameric oligomers named connexons, each one of them placed in the plasma membrane of adjacent cells (Fig. 1) [16]. The connexons can also work as hemichannels providing a direct and highly regulated transmembrane communication pathway [17–19]. The monomer subunit of the hexameric arrangement is the Connexin (Cx), a highly-conserved sequence protein constituted by four hydrophobic transmembrane segments named TM1 to TM4 (Fig. 1) [20, 21]. The N-terminal domain of Cx is inside the cell and it is located within the channel pore determining the polarity of the gap junction channel [8]. Thus, the conformational flexibility...
of this region is crucial for proper regulation of the channel [22]. The C-terminal domains and one of the connecting loops from the Cx26 are also inside the cell, whereas the two others are outside the cell. These last extracellular loops are essential for the docking between connexons. GJCs and connexons hemichannels are sensitive to several intracellular and extracellular factors affecting a variety of physiological processes and pathological states. One of these factors is Ca\(^{2+}\) concentration, which ranging from 2 mM extracellular to 10–100 nM intracellular, is a key element in the regulation of GJC conductance and therefore a driver of multiple physiological properties [5, 19, 23, 24].

A milestone in the field of molecular modelling of connexons occurred when the crystal structure of the GJC of connexin 26 (Cx26) was reported with a resolution of 3.5 Å [25]. GJCs were crystalized with and without Ca\(^{2+}\) [26] and both structures were virtually identical, except from the large structural changes observed in close proximity of Ca\(^{2+}\) binding sites. From the structural knowledge of these systems, several Molecular Dynamics (MD) simulations experiments of the human Cx26 in multiple environments have been carried out [20, 23, 27–29]. In particular, MD simulations have been used to study Ca\(^{2+}\) binding sites at the interface between adjacent subunits close to the extra cellular connexons junction. The importance of this is captured in a recent review article on structure-function relationships on GJCs channel by modelling and simulations by Villanelo el al. [30].

In this work, using calcium as a probe at high concentrations, MD simulations were used to identify potential calcium binding sites of a hemichannel embedded in a model membrane. The MD simulations were conducted taking into account four different cases. These simulations allowed us to explore the various specific amino acids strongly interacting with calcium ions and their dynamics. Furthermore, the position of these amino acids was spatially associated to known pathogenic mutations, using the ClinVar database [31]. In the next sections, we describe the four systems studied and the methodology used in the MD simulations [32]; the results of the simulations and their association with ClinVar annotations. In the Discussion section, we compare our findings with those from the literature. The Conclusions summarize our major findings and discuss how the approach used here may be extended to other systems.

**Materials and Methods**

MD simulations were performed using the GROMACS 5.0.4 software package [33] with the CHARMM36 force-field [34] and the TIP3P model for water [35, 36]. After 10 ns of equilibration, MD simulations were carried out for 500 ns production runs within the NPT (constant number of particles, temperature, and pressure) ensemble. The system was coupled to a temperature bath with a reference temperature of 310K and a relaxation constant of 0.1 ps. Temperature was kept constant using the Nosé-Hoover thermostat [37, 38] with a coupling constant of 6.0 ps and the pressure was equilibrated at 1 bar using the Parrinello-Rahman barostat [39] with a coupling constant of 6.0 ps and compressibility of 4.5×10−5 bar−1. The electrostatic interactions were taken into account using the Particle Mesh Ewald (PME) version of the Ewald sums [40, 41] considering a real space cut off of 1.0 nm, a grid spacing of 0.12 nm and a cubic interpolation. In all the simulations the Van der Waals interactions were cut off at 1.0 nm [42]. The time step for the integration of the equation of
motion was 2 fs. The non-bonded list was updated every 10 steps. All simulations were performed without any constrains. The simulations were performed in the Center of High Computer Performance (CHPC) at the University of Utah, using 120 cores of commodity processors. The figures were obtained using Visual Molecular Dynamics [43] software (VMD from University of Illinois at Urbana-Champaign, IL, USA), Chimera [44] and Grace (http://plasma-gate.weizmann.ac.il/Grace/) software packages.

The simulated systems were based on a Cx26 connexon embedded into a POPC bilayer. The protein structure of the Cx26 was the 3.5 Å X-ray structure of the Connexon Cx26 obtained by Maeda et al. [25] and completed with homology modelling techniques [18]. The protein structure was embedded into a 500 1-palmitoyl-2-oleoylsn-glycero-3-phosphocholine (POPC) (250 in each leaflet) lipid bilayer by the replacement method and using the web based software CHARMM-GUI [45, 46]. POPC lipids are broadly used in biomimetic studies and it is one of the most used systems in this kind of membrane protein MD simulations [47]. The assembled systems were solvated with sufficient number of water molecules (> 46000) to ensure proper hydration of the lipid bilayer and to prevent the interaction of the protein with itself (~25 Å) with periodic boundary conditions (PBC). A sodium chloride solution was used to neutralize the net and local charges of the system.

Even for these big systems, physiological calcium concentration corresponds to 0.1 to 1.7 calcium atoms, which may be insufficient to identify binding sites within a reasonable simulation time. To overcome this, we considered calcium concentrations higher than physiological ones to obtain as broad sample as possible of binding sites. We performed three simulations varying the concentration of calcium and buffer ions, initially placed into the water phase. The calcium ions were randomly placed in the simulation box using a water replace method available in the GROMACS simulation package. These three studies will be referred to as CA–r (with r = 0, 0.04 and 0.1, corresponding to Ca\(^{2+}\) concentration none, 0.04 M and 0.1M, respectively). We carried out an additional simulation at a calcium concentration of 0.1M, were initially eight Ca\(^{2+}\) ions were placed inside the connexon pore, i-CA-0.1. In this case, we replaced random waters and ions present at different sections of the pore editing the initial configurations. All the simulations were run in duplicates.

In Table 1 we summarized the characteristics of each of the systems described above, including the number of atoms, number of different ions and characteristic simulation run times.

Known pathogenic variants of Cx26 (CJB2 gene) were extracted from ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) [31], which is the most comprehensive and authoritative source of annotated human variants with known clinical impact. The search for variants was performed using the web interface of ClinVar in April 17th of 2017 and the variants were recorded manually and assigned against the same Cx26 sequence as used in the simulations (see Discussion section for details). Mutation sites that are far removed from calcium binding sites in the protein sequence may be in their physical proximity and therefore able to change calcium binding ability at the site. To study this issue, we labelled in the Cx26 structure the calcium binding sites and the mutations sites using a pairwise approach and visually identified potential regions of interest.
Results and Discussions

In order to assess the protein structural stability and dynamics during the simulations, we calculated the Root Mean Square Deviation (RMSD) of the protein alpha carbons (Cα) and Root Mean Square Fluctuation (RMSF) of each residue, using as a reference the initial configuration structure of the connexon. Figure 2 compares the RMSD of the CA–0 (green), CA–0.04 (red) and CA–0.1 (black) systems, over 500 ns simulations. The RMSD results for the replicas are presented in Figure S1 of the Supplementary Material. All RMSDs are compatible with a highly stable protein backbone during the simulation time after equilibration. The order of magnitude of the drift from the initial structure was approximately 5 Å for all systems, but it is apparent from Figure 2 that the systems are not fully equilibrated at the beginning of the 500 ns production runs. Therefore, all the analysis presented here disregarded the first 50 ns of the production run, i.e. all average quantities where calculated using the last 450 ns of the simulations to eliminate any transient effects on the results presented here.

To gather insight on the relative fluctuation of different regions within each Cx26 structure we evaluated the RMSF of the backbone of each amino acid residue in the four different chains of the structure (Figure 3) for the last 450 ns of the production runs. RMSF results on the replicas are presented in Figure S2 of the Supplementary Material.

Figure 3 and S2, of the supplementary material, show the average RMSF of each residue of the six connexins chains for the three CA-r simulated systems. Similar fluctuations patterns are observed for the same connexins domains. The highest peak is consistently observed for the CL domain between the residues 96 and 132. The fluctuations observed within the regions of residues 210–226 and 1–19 correspond to the CT and NTH terminal domains. As expected, the CT and CL domains located outside the membrane, are the most flexible ones because their lack of structural constrains. The TM regions are the most stables domains since they are embedded in the lipid bilayer and organized in alpha helices, which restrict their movements. For the NTH domain, we notice subtle differences between the CA–0 simulation and the others, suggesting that the Ca²⁺ ions influence the dynamical properties of this region.

The overall organization of the whole system was investigated through the calculation of the average electron density profile (EDP) along the direction normal to the bilayer (Z-axis) for the three simulations (Figure 4) and its replicas (Figure S3) of the supplementary material. As an example, in Figure 4A and S3A of the supplementary material, we show the EDP of POPC (red), protein (black) and water (green) for the CA–0.1 simulation, where Z=0 corresponds to the bilayer center of mass. The hemichannel asymmetrical structure is reflected in the EDP distribution along the Z-axis. This asymmetry leads to a distortion of the lipid bilayer when compared with plain bilayers and to a high-water density at the region corresponding to the extracellular side of the connexon. Furthermore, contrarily to what is observed in simple lipid membranes, the density of water is different from zero in the hydrophobic region, which could be attributed to the presence of water inside the connexon pore. This was confirmed by visual inspection of the structures generated by the simulation as exemplified in Figure S4 of the Supplementary Material.
Ion electron density profiles and z-averaged density maps (Figures S5 to S6 and S7 to S9) of the supplementary material show that most sodium and chloride ions are widely distributed into the water phase. However, few of the ions are found in the outer region of the pore and some chloride ions were able to enter inside the pore during the simulation times considered here.

Figure 4B and S3B of the supplementary material, show the calcium distribution for CA–0.1 (green) and CA–0.04 (blue) simulations and its replicas, respectively. Similar patterns are observed in both cases, with well-defined peaks (~−20Å, ~20Å and ~40 Å) at the protein edges. The first peak had the same high for both concentrations suggesting a saturation of Ca$^{2+}$ binding sites, while the second and third peaks show an increase in their intensities with the calcium concentration. This could be explained by a difference in the total number of Ca$^{2+}$ binding sites on each side of the protein, as is discussed below. No Ca$^{2+}$ ions were found around at Z=0, but in one case in the replicated system (Figure S3B-green), it seems that a calcium ion was able to enter the pore. This is supported by the analysis of calcium density maps (S8D, S8H and S9D-S9H) and will be discussed below.

An exploratory analysis of the CX26 pore topology was carried out using the MOLE online service [54]. Through this tool, we were able to probe the pore length, characterize its bottleneck and measure different diameters. In Figures S10 and S11 of the Supplementary Material, three snapshots of structures analysed at 100 ns (A), 300 ns (B) and 500 ns (C), for CA-0.0 and CA-01, are presented at the top of the figure along with a plot of the corresponding channel length and radius at the bottom. Our results are in good agreement with the ones reported by Batool et al. [55] both in pore size and length. However, as it can be observed in the figure S11, in our work we found that high Ca$^{2+}$ concentrations appear to be altering the intracellular topology of the pore. This issue will be explore in future work.

The Ca$^{2+}$ interactions with specific amino acids were studied by calculating the time evolution distances between the ions and the selected atoms in the trajectories from simulations. Stable distances can be associated to stable energies, considering pair interactions between non-bonded atoms. Further information could be obtained by free energy calculation, but we consider that those calculations are outside the scope of this work, which focus in identifying potential binding sites and associate them with known pathogenic variances.

Figure 5 shows the temporal evolution of the distance between a Ca$^{2+}$ and the two carboxylic oxygen atoms in the lateral chain of ASP50 for one of the Cx26 protomers. The distance corresponds to each oxygen atom to the calcium ion (R1 = Oxygen 1 to Ca$^{2+}$ -red- and R2 = Oxygen 2 to Ca$^{2+}$ -black) during the first 100ns were the interplay between the three atoms is better observed. The distances at the initial times (t < 25 ns), are ~50 Å and exhibit large fluctuations, but after 25 ns the distances remain close to 2.35 Å, indicating a specific interaction, such as the one depicted in the inset of Figure 5. In Figure S12 of the Supplementary Material we present the time evolution of these distances up to 500 ns confirming the stability.
We found several other amino acids interacting with Ca$^{2+}$ and following similar behaviors: a large initial uncorrelated fluctuation of the distances between Ca$^{2+}$ and the lateral-chain-carboxylic oxygens followed by stabilization at a distance of ~2.35 Å. These amino acids are ASP159 in the E2 domain, GLU114, ASP117, GLU119, and GLU120 in the CL domain, VAL226 in the CT domain and ASP50 in the E1 domain.

ASP50 was already identified as a calcium binding site by Zonta et al. [23]. This finding was also supported by Lopez et al. [56], that using mutant structures of Cx26(D50N/Y) were the ASP50 was replaced by neutral amino acids Tyrosine or Asparagine concluded that ASP50 plays a key role in the Ca$^{2+}$ driven gating mechanism. Recently, using MD, the same authors reported that there is an electrostatic network close to the E1 region that exhibits significant disruption/rearrangement upon calcium binding [16]. In spite of the symmetry of the protein, in our simulations, the ASP50 interaction is observed only in one protomer of the connexon at a time, which may be associated with the electrostatic repulsion of a neighboring chain [26].

We were also able to associate GLU114, GLU119 and GLU120 acids with calcium binding sites and to the best of our knowledge this is the first time that this has been reported. These three amino acids were identified to be capable of being γ-carboxylated in some cells as part of post-translational modifications [57] and a mutation in GLU114 was associated with severe deafness in association with a V27I mutation [58]. To the best of our knowledge, ASP117 was not previously reported in association with a calcium binding site. This amino acid belongs to the CL region close to GLU114, GLU119 and GLU120 amino acid.

This is also the first time that a direct link between ASP159 and calcium binding is observed. Gonzalez et al. [59] demonstrated that human and sheep Cx26, but not the rat orthologue, are able to form open, voltage-activated hemichannels. They also showed that rat hemichannels became voltage-gated when the Aspartate found in the human and sheep replaced the Asparagine at position 159 of the rat sequence. The C-terminal residue VAL226 is also a new calcium binding site found in this study but given it’s terminal nature is possible that may not be relevant.

We identified a different total number of Ca$^{2+}$ binding sites on each side of the connexon: seven in the extra-cellular and thirty in the intra-cellular side. From Figure 4B and S3B of the supplementary material, we observed that increasing calcium concentration leads to populating these Ca$^{2+}$ sites corresponding to EDP peaks at ~20 Å and ~40 Å. These regions are the most flexible ones and involve ASP, GLU and VAL residues that are further away from the center of the connexon.

Under ergodic conditions all accessible binding sites will be revealed, however this is not the case for finite simulation. In order to extensively sample all possible binding sites different strategies are needed. The first one used here was to study different calcium concentration. Another strategy would be to bias the initial placement of the calcium in the simulations. In order to do so, we performed a simulation on a system named as i-CA-0.1 (see Methods) - in which eight Ca$^{2+}$ ions were placed inside the Cx26 channel and the other Ca$^{2+}$ randomly distributed. RMSD, RMSF and membrane-protein overall organization were analyzed for the
duplicate cases. The results of these calculations are presented in Figures S13 to S15 of the supplementary material. At a first glance, no significant differences with the results discussed above for the other systems considered here were found. However, for this simulation the calcium EDP showed a new peak on the distribution at the center of the pore (Z=0), as shown in figure S15B of the supplementary material. This is in correlation with the density maps analysis, where calcium density is concentrated inside the pore (Figure S17D and S17H), a main difference with it was observed for the previous density maps. With further analysis of the simulations, we were able to identify in this area a calcium binding site involving ASP2 from two connexins. According to the literature reports [51, 60], this interaction may be physiologically relevant due to the role of ASP2 in the “plug gating mechanism”, as discussed elsewhere this suggest that Ca²⁺ binding at ASP2 also may be associated with this mechanism. Visual analysis of the MD trajectories also supports this observation as exemplified in S18 of the supplementary material.

In addition to those sites described above and in agreement with an X-ray structure reported in the literature [26], in the i−CA–0.1 simulation we found calcium binding sites involving GLU42, GLU47 and GLY45, which are located at the extracellular edge of the pore region. We were able to find three stable supra-molecular arrangements of Ca²⁺ interaction within these sites, which are shown in Fig. 6. The first arrangement (6A, 6B) involves the oxygen atoms of the GLU42 lateral chain (red-black) and the GLU47 lateral chain (green-blue) stabilizing, at similar distances (~2.5 Å), and the oxygen of the GLY45 (orange), stabilizing at a distance between 5 Å and 7 Å. In the second arrangement (6C, 6D) the two oxygen atoms of GLU42 (red-black) are located at a stable distance (~2.3Å) of a Ca²+ and only one oxygen of the GLU47 (green or blue) binds at any given time. The oxygens exchange between GLU47, green to blue, can be observed in Fig. 6C at approximately 35 ns. In addition, the GLY45 oxygen distance to the Ca²⁺ fluctuates around a mean value of 5 Å. The third arrangement (6E and 6F) shows that one of the oxygen atoms of GLU47 (green) is at ~2.3 Å from the Ca²+. Large fluctuations are observed for the oxygens atoms in GLU42 (red-black), whereas the oxygen of GLY45 (orange) remains at a distance similar to the other oxygen of GLU47 (blue).

In relation with these amino acids, Bennet et al. reported the interaction between them and a calcium ion by X-ray crystallography [26]. In this work, an electrostatic barrier driven by Ca²⁺ for the GLY45 in coordination with GLU42 and GLU47 was proposed. However, as a final remark, the authors doubted about the strength of GLY45 role in this arrangement. In our simulations, the GLY45 residue is found at a longer distance from the calcium that the one reported by the X-ray studies. Moreover, here GLY45 appears to be repelled by the changes in the total force from the calcium ion and the GLU42 and GLU47 from adjacent connexins. This behavior supports Bennet et al. theory that GLY45 was not a stable participant on this complex network. These results exemplify the strength of un-constrained MD simulations to study the dynamic behavior of these kinds of systems that escapes some experimental approaches.

It is important to also notice that the interaction of GLU47 and calcium was studied by the means of quantum chemistry methods by Zonta et al. [61]. Through their calculations, the researchers explored GLU47, ARG75 and ARG184 with Ca²⁺ in a Cx26 hemichannel and
their results proved that the post-translational glutamate GLU47 is a strong candidate to bind Ca\(^{2+}\) in the extracellular side on Cx26. However, the computational cost of the calculations is too high and then the procedure might be applicable exceptionally to confirm an argued mechanism of interaction, as the authors did.

Because Ca\(^{2+}\) ion regulation plays a key role in defining the physiological activity of the connexons we hypothesize that mutations in close proximity (in sequence or physical proximity, see also Methods section) of Ca\(^{2+}\) ion binding sites are more likely to cause pathological alterations. However, very little is known with respect to the molecular mechanisms of diseases associated with these variants. Figure 7 shows the sequence of Cx26, where the Ca\(^{2+}\) binding sites and mutation sites obtained from ClinVar have been highlighted.

Figure 7 shows that there are Ca\(^{2+}\) binding sites for which pathogenic variants have been reported, i.e. GLU120 and ASP159. Moreover, a number of calcium binding sites are one or two residues apart from a reported mutation site [11, 12, 15, 62–64]. While these observations are important, it is also relevant to take into account the three-dimensional nature of our problem. Mutation sites that are far from calcium binding sites in the protein sequence may be in physical proximity and therefore, able to change calcium binding ability at the site. To study this issue, we labelled in the Cx26 structure the calcium binding sites and the mutations sites using a pairwise approach and visually identified potential regions of interest (see Figure 8 for an example).

The summarization of these analysis is presented in Table 2, where we show all the possible regions of interaction between sites with reported pathogenic mutations (ClinVar) and Ca\(^{2+}\) binding sites found in the MD simulations. In all cases these results have been derived from visual inspection and using an inclusive criterion. Also, in Table 2 we associate our findings with the recently reported [11, 12] functional state of Cx26 hemichannels, gap-junctions and pathological phenotypes [64]. It is important to notice that due to the three-dimensional approach used here to identify the possible associations between reported mutations and calcium-binding sites from the MD simulations, some mutations are at a distant region of the sequence from that where we find calcium binding sites. This is for example the case of G12R and VAL226 as exemplified in figure S19 of the supplementary material.

Conclusions

In this work, we carried out eight simulations considering different calcium concentration and initial conditions. Our results were able to capture interesting features of the calcium-connexon interaction. In particular we identified 10 amino acid involved in specific interaction sites, which are summarized them in Figure 9. Besides the agreement that we found with the specific sites for calcium already defined in literature, in our work we identified novel ones and went forward capturing different kind of arrangements that could shed light to the interaction of calcium with Cx26. In addition, a summary of the number of calcium ions in relation with these residues is presented in Table S1 of the Supplementary Material.
Given the relevance of calcium in the physiopathology of conditions that affect the Cx26 connexon channel activity \[11, 12, 21\] it is important to have an insight on the molecular interactions of these two key components. In this work, using calcium as a probe at high concentrations, we found the first indication of different calcium sites through the electron density profile. Further inspection at the molecular level helped us to find specific amino acid interactions with calcium and their dynamics. This interaction mainly occurs with the carboxyl groups of the amino acids, similar to what it was described for other compounds as it can be exemplified by the chelation mechanism of the calcium by the functional groups of the PAMAM and EDTA \[118\].

Molecular Dynamics simulations proved to be a powerful tool to explore a biological system at the molecular level. The identification of the specific sites where calcium could have an important role in the connexon structure is a step forward to understand the complex world of the intercellular communication. Moreover, by combining the MD results with known pathogenic mutation sites, we were able to find regions of the protein for which in depth studies of how mutations affect structure and dynamics of calcium binding may elucidate pathogenic pathways and perhaps identified potential therapeutic avenues.

We suggest further research, including MD simulation in mutated proteins, to further explore these systems, and dedicated in vitro experiments. While our work has been restricted to Cx26, the methods proposed here could be extended to other connexins for which experimental structures are available or by using 3D structure prediction approaches \[119\]. Both, the connexinopathies understanding and the development of new therapies will benefit from the knowledge at the molecular level of these systems.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgements:**

The Center for High Performance Computing at The Utah University provided computer resources for High Performance Computing. JCF has been partially supported by the University of Utah Center for Clinical and Translational Science under NCATS Grant U01TR002538. NM and MBF have been partially supported by the University of Buenos Aires Grant 20020130100039BA and PIP CONICET 11220130100377. JMRA has been partially supported by the Florencio Fiorini Foundation. MP have been partially supported by grants ANPCyT PICT 2014– 3653 and PIP CONICET 0131–2014. MP have been partially supported by the University of Buenos Aires Grant 20020130200138BA.

**References**

1. Trosko JE, Ruch RJ. Cell-cell communication in carcinogenesis. Front Biosci. 1998;3:d208–36. doi: 10.2741/A275. PubMed PMID: 9458335. [PubMed: 9458335]
2. Vinken M Introduction: Connexins, pannexins and their channels as gatekeepers of organ physiology. Cellular and Molecular Life Sciences. 2015;72:2775–8. doi: 10.1007/s00018-015-1958-3. [PubMed: 26084871]
3. Mab Vinken, Ta Vanhaecke, Pa Papeleu, Sa Snykers, Ta Henkens, Va Rogiers. Connexins and their channels in cell growth and cell death. Cellular Signalling. 2006;18:592–600. doi: 10.1016/j.cellsig.2005.08.012. [PubMed: 16183253]
4. Evans WH, Martin PEM. Gap junctions: structure and function (Review). Molecular Membrane Biology. 2002;19:121–36. doi: 10.1080/09687680210139839. PubMed PMID: 12126230. [PubMed: 12126230]

5. Peracchia C. Chemical gating of gap junction channels: Roles of calcium, pH and calmodulin. Biochimica et Biophysica Acta - Biomembranes. 2004;1662:61–80. doi: 10.1016/j.bbamem.2003.10.020. PubMed PMID: 15033579.

6. Hanner F, Sorensen CM, Holstein-Rathlou NH, Peti-Peterdi J. Connexins and the kidney. American journal of physiology Regulatory, integrative and comparative physiology. 2010;298:R1143–55. doi: 10.1152/ajpregu.00808.2009. PubMed PMID: 20164205.

7. Scott CA, Tattersall D, O’Toole EA, Kelsell DP. Connexins in epidermal homeostasis and skin disease. Biochimica et Biophysica Acta - Biomembranes. 2012;1818:1952–61. doi: 10.1016/j.bbamem.2011.09.004. PubMed PMID: 21933662.

8. Nielsen MS, Axelsen LN, Sorgen PL, Verma V, Delmar M, Holstein-Rathlou NH. Gap junctions. Comprehensive Physiology. 2012;2:1981–2035. doi: 10.1002/cphy.c110051. PubMed PMID: 23723031. [PubMed: 23723031]

9. Figueroa XF, Duling BR. Gap junctions in the control of vascular function. Antioxidants & redox signaling. 2009;11:251–66. doi: 10.1089/ars.2008.2117. PubMed PMID: 18831678. [PubMed: 18831678]

10. Elias LA, Wang DD, Kriegstein AR. Gap junction adhesion is necessary for radial migration in the neocortex. Nature. 2007;448:901–7. doi: 10.1038/nature06063. PubMed PMID: 17713529. [PubMed: 17713529]

11. García IE, Prado F, Pupo A, Jara O, Rojas-Gómez D, Mujica P, et al. Connexinopathies: a structural and functional glimpse. BMC Cell Biology. 2016;17:517. doi: 10.1186/s12860-016-0092-x. PubMed PMID: 27228968.

12. Srinivas V, Verselis VK, White TW. Human diseases associated with connexin mutations. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2017. doi: 10.1016/j.bbamem.2017.04.024. PubMed PMID: 28457858.

13. Delmar M, Makita N. Cardiac connexins, mutations and arrhythmias. Current Opinion in Cardiology. 2012;27:236–41. doi: 10.1097/HCO.0b013e328352220e. PubMed PMID: 22382502. [PubMed: 22382502]

14. Kelsell DP, Dunlop J, Stevens HP, Lench NJ, Liang JN, Parry G, et al. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. Nature. 1997;387:80–3. doi: 10.1038/387080a0. PubMed PMID: 9139825. [PubMed: 9139825]

15. Heathcote K, Syrris P, Carter ND, Patton Ma. A connexin 26 mutation causes a syndrome of sensorineural hearing loss and palmar plantar hyperkeratosis (MIM 148350). Journal of medical genetics. 2000;37:50–3. doi: 10.1136/jmg.37.1.50. PubMed PMID: 10633135. [PubMed: 10633135]

16. Beyer EC, Berthoud VM. Gap junction structure: unraveled, but not fully revealed. F1000Research. 2017;6:568. doi: 10.12688/f1000research.10490.1. PubMed PMID: 28529713. [PubMed: 28529713]

17. Bennett MVL, Contreras JE, Bukauskas FF, Sáez JC. New roles for astrocytes: Gap junction hemichannels have something to communicate. Trends in Neurosciences. 2003;26:610–7. doi: 10.1016/j.tins.2003.09.008. PubMed PMID: 14585601. [PubMed: 14585601]

18. Hung A, Yarovsky I. Gap junction hemichannel interactions with zwitterionic lipid, anionic lipid, and cholesterol: Molecular simulation studies. Biochemistry. 2011;50:1492–504. doi: 10.1021/bi1004156. PubMed PMID: 21244055. [PubMed: 21244055]

19. Lopez W, Ramachandran J, Alsamarah A, Luo Y, Harris AL, Contreras JE. Mechanism of gating by calcium in connexin hemichannels. Proceedings of the National Academy of Sciences. 2016;201609378. doi: 10.1073/pnas.1609378113.

20. Pantano S, Zonta F, Mammano F. A fully atomistic model of the Cx32 connexon. PLoS ONE. 2008;3:1–11. doi: 10.1371/journal.pone.0002614. PubMed PMID: 18648547.

21. Yeager M, Harris AL. Gap junction channel structure in the early 21st century: facts and fantasies. Current Opinion in Cell Biology. 2007;19:521–8. doi: 10.1016/jceb.2007.09.001. PubMed PMID: 17945477. [PubMed: 17945477]
22. Kyle JW, Minogue PJ, Thomas BC, Domowicz DaL, Berthoud VM, Hanck Da, et al. An intact connexin N-terminus is required for function but not gap junction formation. Journal of cell science. 2008;121:2744–50. doi: 10.1242/jcs.032482. PubMed PMID: 18664489. [PubMed: 18664489]

23. Zonta F, Polles G, Zanotti G, Mammano F. Permeation pathway of homomeric connexin 26 and connexin 30 channels investigated by molecular dynamics. Journal of biomolecular structure & dynamics. 2012;29:985–98. doi: 10.1080/073911012010525027. PubMed PMID: 22292956. [PubMed: 22292956]

24. Zhang Y, Tang W, Ahmad S, Sipp Ja, Chen P, Lin X. Gap junction-mediated intercellular biochemical coupling in cochlear supporting cells is required for normal cochlear functions. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:15201–6. doi: 10.1073/pnas.0501859102. PubMed PMID: 16217030. [PubMed: 16217030]

25. Maeda S, Nakagawa S, Suga M, Yamashita E, Oshima A, Fujiyoshi Y, et al. Structure of the connexin 26 gap junction channel at 3.5 A resolution. Nature. 2009;458:597–602. doi: 10.1038/nature07869. PubMed PMID: 19340074. [PubMed: 19340074]

26. Bennett BC, Purdy MD, Baker KA, Acharya C, McIntire WE, Stevens RC, et al. An electrostatic mechanism for Ca(2+)-mediated regulation of gap junction channels. Nat Commun. 2016;7:8770. doi: 10.1038/ncomms9770. PubMed PMID: 26753910. [PubMed: 26753910]

27. Zonta F, Buratto D, Cassini C, Bortolozzi M, Mammano F. Molecular dynamics simulations highlight structural and functional alterations in deafness-related M34T mutation of connexin 26. Frontiers in Physiology. 2014;5:1–9. doi: 10.3389/fphys.2014.00085. PubMed PMID: 24624091. [PubMed: 24478714]

28. Kwon T, Roux B, Jo S, Klauda JB, Harris AL, Bargiello TA. Molecular dynamics simulations of the Cx26 hemichannel: insights into voltage-dependent loop-gating. Biophysical journal. 2012;102:1341–51. doi: 10.1016/j.bpj.2012.02.009. PubMed PMID: 22455917. [PubMed: 22455917]

29. Araya-Secchi R, Perez-Acle T, Kang SG, Huynh T, Bernardin A, Escalona Y, et al. Characterization of a novel water pocket inside the human Cx26 hemichannel structure. Biophysical journal. 2014;107:599–612. doi: 10.1016/j.bpj.2014.05.037. PubMed PMID: 25099799. [PubMed: 25099799]

30. Villanelo F, Escalona Y, Pareja-Barrueto C, Garate JA, Skerrett IM, Perez-Acle T. Accessing gap-junction channel structure-function relationships through molecular modeling and simulations. BMC Cell Biology. 2017;18:5. doi: 10.1186/s12860-016-0121-9. PubMed PMID: 28124624.

31. Landrum MJ, de Paula E, Pickholz M. Molecular Dynamics Simulations to Study Drug Delivery Systems. In: Vakhrushev A, editor. Molecular Dynamics IntechOpen; 2018.

32. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25. doi: 10.1016/j.softx.2015.06.001. PubMed PMID: 22713035.

33. Best RB, Zhu X, Shim J, Lopes PEM, Mittal J, Feig M, et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone and side-chain and Dihedral Angles. Journal of Chemical Theory and Computation. 2012;8:3257–73. doi: 10.1021/ct300400x. PubMed PMID: 23341755. [PubMed: 23341755]

34. Wu Y, Tepper HL, Voth GA. Flexible simple point-charge water model with improved liquid-state properties. The Journal of chemical physics. 2006;124:024503. doi: 10.1063/1.2136877. PubMed PMID: 16422607. [PubMed: 16422607]

35. Mahoney MW, Jorgensen WL. A five-site model for liquid water and the reproduction of the density anomaly by rigid, nonpolarizable potential functions. The Journal of chemical physics. 2000;112:8910. doi: 10.1063/1.481505. PubMed PMID: 86851200022.

36. Nosé S A unified formulation of the constant temperature molecular dynamics methods. J Chem Phys. 1984;81:511. doi: 10.1063/1.447334.
38. Hoover WG. Canonical dynamics: Equilibrium phase-space distributions. Physical Review A. 1985;31:1695–7. doi: 10.1103/PhysRevA.31.1695. PubMed PMID: 9895674.

39. Parrinello M, Rahman A. Strain fluctuations and elastic constants. The Journal of chemical physics. 1982;76:2662–6. doi: 10.1063/1.443248. PubMed PMID: 25246403.

40. Ewald PP. Die berechnung Optischer und Elektrostatisher Gitterpotentiale. Ann Phys. 1921;64:253–87.

41. Herce HD, Garcia AE, Darden T. The electrostatic surface term: (I) periodic systems. The Journal of chemical physics. 2007;126:214106. doi: 10.1063/1.2714527. [PubMed PMID: 17411107]

42. Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load balanced, and scalable molecular simulations. J Chem Theory and Comput. 2008;4:435–47. doi: 10.1021/ct700301q. [PubMed PMID: 26620784]

43. Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. Journal of Molecular Graphics. 1996;14:33–8. doi: 10.1016/0263-7855(96)00018-5. PubMed PMID: 8744570.

44. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. Journal of computational chemistry. 2004;25(13):1605–12. Epub 2004/07/21. doi: 10.1002/jcc.20084. PubMed PMID: 15264254. [PubMed: 15264254]

45. Jo S, Kim T, Iyer V, Im W. CHARMM GUI: a web based graphical user interface for CHARMM. Journal of computational chemistry. 2008;29:1859–65. doi: 10.1002/jcc.20945. [PubMed: 18351591]

46. Wu EL, Cheng X, Jo S, Rui H, Song KC, Dávila-Contreras EM, et al. CHARMMGUI Membrane Builder toward realistic biological membrane simulations. Journal of computational chemistry. 2014;35:1997–2004. doi: 10.1002/jcc.23702. [PubMed: 25130509]

47. Zonta F, Polles G, Zanotti G, Mammano F. Permeation Pathway of Homomeric Connexin 26 and Connexin 30 Channels Investigated by Molecular Dynamics. Journal of Biomolecular Structure and Dynamics. 2012;29(5):985–98. doi: 10.1080/073911012010525027. [PubMed: 22292956]

48. Kabach WA solution for the best rotation to relate two sets of vectors. Acta Crystallographica Section A. 1976;32:922–3. doi: 10.1107/S056773947601873. PubMed PMID: 96.

49. Vendome J, Posy S, Jin X, Bahna F, Ahlsen G, Shapiro L, et al. Molecular design principles underlying β-strand swapping in the adhesive dimerization of cadherins. Nature Structural & Molecular Biology. 2011;18:693–700. doi: 10.1016/j.biotechadv.2011.08.021.Secreted. PubMed PMID: 100000221.

50. Capener CE, Sansom MSP. Molecular Dynamics Simulations of a K Channel Model: Sensitivity to Changes in Ions, Waters, and Membrane Environment. The Journal of Physical Chemistry B. 2002;106:4543–51. doi: 10.1021/jp0129986.

51. Structure Oshima A. and closure of connexin gap junction channels. FEBS Letters. 2014;588:1230–7. doi: 10.1016/j.febslet.2014.01.042. PubMed PMID: 24492007. [PubMed: 24492007]

52. Pickholz M, Fernandes Fraceto L, de Paula E. Distribution of neutral prilocaine in a phospholipid bilayer: Insights from molecular dynamics simulations. International Journal of Quantum Chemistry. 2008;108:2386–91. doi: 10.1002/qua.21767.

53. Pasenkiewicz-Gierula M, Takaoka Y, Miyagawa H, Kitamura K, Kusumi A. Charge pairing of headgroups in phosphatidylcholine membranes: A molecular dynamics simulation study. Biophysical journal. 1999;76:1228–40. doi: 10.1016/S0006-3495(99)77286-3. PubMed PMID: 10049307. [PubMed: 10049307]

54. Pravda L, Sehnal D, Tousek D, Navratilova V, Bazgier V, Berka K, et al. MOLEonline: a web-based tool for analyzing channels, tunnels and pores (2018 update). Nucleic acids research. 2018;46(W1):W368–w73. Epub 2018/05/03. doi: 10.1093/nar/gky309. PubMed PMID: 29718451; PubMed Central PMCID: PMC5630847. [PubMed: 29718451]

55. Batool A, Yasmeen S, Rashid S. T8M mutation in connexin-26 impairs the connexon topology and shifts its interaction paradigm with lipid bilayer leading to nonsyndromic hearing loss. Journal of Molecular Liquids. 2017;227(C):168–77. doi: 10.1016/j.molliq.2016.12.018.
56. Lopez W, Gonzalez J, Liu Y, Harris AL, Contreras JE. Insights on the mechanisms of Ca(2+) regulation of connexin26 hemichannels revealed by human pathogenic mutations (D50N/Y). The Journal of general physiology. 2013;142:23–35. doi: 10.1085/jgp.201210893. PubMed PMID: 23797420. [PubMed: 23797420]

57. Locke D, Koreen IV, Harris AL. Isoelectric points and post-translational modifications of connexin26 and connexin32. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2006;20:1221–3. doi: 10.1096/fj.05-5309fj. PubMed PMID: 16645047.

58. Nemoto-Hasebe I, Akiyama M, Yamada N, Inoue Y, Touge C, Shimizu H. Keratitis-ichthyosis-deafness syndrome lacking subjective hearing impairment. Acta Dermato-Venereologica. 2008;88:406–8. doi: 10.2340/00015555-0457. PubMed PMID: 18709320. [PubMed: 18709320]

59. González D, Gómez-Hernández JM, Barrio LC. Species specificity of mammalian connexin-26 to form open voltage-gated hemichannels. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2006;20:2329–38. doi: 10.1096/fj.06-5828com. PubMed PMID: 17077310. [PubMed: 17077310]

60. Maeda S, Tsukihara T. Structure of the gap junction channel and its implications for its biological functions. Cellular and Molecular Life Sciences. 2011;68:1115–29. doi: 10.1007/s00018-010-0551-z. [PubMed: 20960023]

61. Zonta F, Mamman F, Torsell M, Fortunat N, Oria L, Polimen A. Role of gamma carboxylated Glu47 in connexin 26 hemichannel regulation by extracellular Ca2+: insight from a local quantum chemistry study. Biochemical and biophysical research communications. 2014;445:10–5. doi: 10.1016/j.bbrc.2014.01.063. PubMed PMID: 24468086. [PubMed: 24468086]

62. Kelsell DP, Di W-L, Houseman MJ. Connexin Mutations in Skin Disease and Hearing Loss. Am J Hum Genet. 2001;68:559–68. doi: 10.1086/318803. PubMed PMID: 11179004. [PubMed: 11179004]

63. Bavamian S, Klee P, Allagnat F, Haefliger JA, Meda P. Connexins and secretion. Connexins: A Guide. Totowa, NJ: Humana Press; 2009 p. 511–27.

64. Snoeckx RL, Huygen PL, Feldmann D, Marlin S, Denoyelle F, Waligora J, et al. GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet. 2005;77:945–57. doi: 10.1086/497996. PubMed PMID: 16380907. [PubMed: 16380907]

65. Lee JR, Derosa AM, White TW. Connexin mutations causing skin disease and deafness increase hemichannel activity and cell death when expressed in Xenopus oocytes. The Journal of investigative dermatology. 2009;129:870–8. doi: 10.1038/jid.2008.335. PubMed PMID: 18987669. [PubMed: 18987669]

66. García IE, Maripillán J, Jara O, Ceriani R, Palacios-Muñoz A, Ramachandran J, et al. Keratitis-Ichthyosis-Deafness Syndrome-Associated Cx26 Mutants Produce Nonfunctional Gap Junctions but Hyperactive Hemichannels When Co-Expressed With Wild Type Cx43. Journal of Investigative Dermatology. 2015;135:1338–47. doi: 10.1038/jid.2015.20. PubMed PMID: 25625422. [PubMed: 25625422]

67. Choi S-Y, Lee KY, Kim H-KH-J, Kim H-KH-J, Chang Q, Park H-J, et al. Functional evaluation of GJB2 variants in nonsyndromic hearing loss. Molecular medicine. 2011;17:550–6. doi: 10.2119/molmed.2010.00183. PubMed PMID: 21298213. [PubMed: 21298213]

68. García-Jaramillo M, Calm R, Bondia J, Tarín C, Vehí J. Insulin dosage optimization based on prediction of postprandial glucose excursions under uncertain parameters and food intake. Computer Methods and Programs in Biomedicine. 2012;105:61–9. doi: 10.1016/j.cmpb.2010.08.007. [PubMed: 20870309]

69. Martin PEM, Coleman SL, Casalotti SO, Forge A, Howard Evans W. Properties of Connexin26 Gap Junctional Proteins Derived from Mutations Associated With Non-Syndromal Hereditary Deafness. Human Molecular Genetics. 1999;8:2369–76. doi: 10.1093/hmg/8.13.2369. PubMed PMID: 10556284. [PubMed: 10556284]

70. Zhang J, Scherer SS. Dominant Cx26 mutants associated with hearing loss have dominant-negative effects on wild type Cx26. Molecular and Cellular Neuroscience. 2011;47:71–8. doi: 10.1016/j.mcn.2010.10.002. PubMed PMID: 21040787. [PubMed: 21040787]
71. Yum SW, Zhang J, Scherer SS. Dominant connexin26 mutants associated with human hearing loss have trans-dominant effects on connexin30. Neurobiology of Disease. 2010;38:226–36. doi: 10.1016/j.nbd.2010.01.010. PubMed PMID: 20096356. [PubMed: 20096356]

72. Rouan F, White TW, Brown N, Taylor AM, Lucke TW, Paul DL, et al. Trans-Dominant Inhibition of Connexin-43 By Mutant Connexin-26: Implications for Dominant Connexin Disorders Affecting Epidermal Differentiation. Journal of cell science. 2001;114:2105–13. PubMed PMID: 11493646. [PubMed: 11493646]

73. Choi S-Y, Park H-J, Lee KY, Dinh EH, Chang Q, Ahmad S, et al. Different functional consequences of two missense mutations in the GJB2 gene associated with non-syndromic hearing loss. Hum Mutat. 2009;30:E716–E27. doi: 10.1002/humu.21036. PubMed PMID: 19384972. [PubMed: 19384972]

74. Bruzzone R, Gomès D, Denoyelle E, Duval N, Perea J, Veronesi V, et al. Functional analysis of a dominant mutation of human connexin26 associated with nonsyndromic deafness. Cell communication & adhesion. 2001;8:425–31. PubMed PMID: 12064630. [PubMed: 12064630]

75. Tekin M, Arnos KS, Xia XJ, Oelrich MK, Liu XZ, Nance WE, et al. W44C mutation in the connexin 26 gene associated with dominant non-syndromic deafness. Clinical genetics. 2001;59:269–73. doi: 10.1034/j.1399-0004.2001.590409.x. PubMed PMID: 11298683. [PubMed: 11298683]

76. Da Gerido, DeRosa AM, Richard G, White TW. Aberrant hemichannel properties of Cx26 mutations causing skin disease and deafness. American journal of physiology Cell physiology. 2007;293:C337–C45. doi: 10.1152/ajpcell.00626.2006. PubMed PMID: 17428836. [PubMed: 17428836]

77. Sanchez HA, Verselis VK. Aberrant Cx26 hemichannels and keratitis-ichthyosis deafness syndrome: insights into syndromic hearing loss. Frontiers in cellular neuroscience. 2014;8:354. doi: 10.3389/fncel.2014.00354. PubMed PMID: 25386120. [PubMed: 25386120]

78. Sánchez Ha, Mese G, Srinivas M, White TW, Verselis VK. Differentially altered Ca2+ regulation and Ca2+ permeability in Cx26 hemichannels formed by the A40V and G45E mutations that cause keratitis ichthyosis deafness syndrome. The Journal of general physiology. 2010;136:47–62. doi: 10.1085/jgp.201010433. PubMed PMID: 20584891. [PubMed: 20584891]

79. Stong BC, Chang Q, Ahmad S, Lin X. A novel mechanism for connexin 26 mutation linked deafness: cell death caused by leaky gap junction hemichannels. The Laryngoscope. 2006;116:2205–10. doi: 10.1097/01.mlg.0000241944.77192.d2. PubMed PMID: 17146396. [PubMed: 17146396]

80. Ogawa Y, Takeuchi T, Kono M, Hamajima N, Yamamoto T, Sugiiura K, et al. Revertant Mutation Releases Confined Lethal Mutation, Opening Pandora’s Box: A Novel Genetic Pathogenesis. PLoS Genetics. 2014;10:e1004276. doi: 10.1371/journal.pgen.1004276. PubMed PMID: 24785414. [PubMed: 24785414]

81. Oguchi T, Ohitsuka A, Hashimoto S, Oshima A, Abe S, Kobayashi Y, et al. Clinical features of patients with GJB2 (connexin 26) mutations: Severity of hearing loss is correlated with genotypes and protein expression patterns. Journal of Human Genetics. 2005;50:76–83. doi: 10.1007/s10038-004-0223-7. PubMed PMID: 15700112. [PubMed: 15700112]

82. Palmada M, Schmalisch K, Böhmer C, Schug N, Pfister M, Lang F, et al. Loss of function mutations of the GJB2 gene detected in patients with DFNB1-associated hearing impairment. Neurobiology of disease. 2006;22:112–8. doi: 10.1016/j.nbd.2005.10.005. PubMed PMID: 16300957. [PubMed: 16300957]

83. Tóth T, Kupka S, Haack B, Riemann K, Braun S, Fazakas F, et al. GJB2 mutations in patients with non-syndromic hearing loss from Northeastern Hungary. Hum Mutat. 2004;23:631–2. doi: 10.1002/humu.9250. PubMed PMID: 15146474.

84. Marziano NK, Casalotti SO, Portelli AE, Becker DL, Forge A. Mutations in the gene for connexin 26 (GJB2) that cause hearing loss have a dominant negative effect on connexin 30. Human Molecular Genetics. 2003;12:805–12. doi: 10.1093/hmg/ddg076. PubMed PMID: 12668604. [PubMed: 12668604]

85. Chen Y, Deng Y, Bao X, Reuss L, Altenberg GA. Mechanism of the defect in gap-junctional communication by expression of a connexin 26 mutant associated with dominant deafness. FASEB
journal : official publication of the Federation of American Societies for Experimental Biology.
2005;19:1516–8. doi: 10.1096/fj.04-3491fje. PubMed PMID: 16009703. [PubMed: 16009703]

86. Iossa S, Marciano E, Franzé A. GJB2 Gene Mutations in Syndromic Skin Diseases with Sensorineural Hearing Loss. Current genomics. 2011;12:475–78. doi: 10.2174/138920211797904098. PubMed PMID: 22547955. [PubMed: 22547955]

87. Bruzzone R, Veronesi V, Gomès D, Bicego M, Duval N, Marlin S, et al. Loss-of-function and residual channel activity of connexin26 mutations associated with non-syndromic deafness. FEBS Letters. 2003;533:79–88. doi: 10.1016/S0014-5793(02)03755-9. PubMed PMID: 12505163. [PubMed: 12505163]

88. Bajaj Y, Sirimanna T, Albert DM, Qadir P, Jenkins L, Bitner-Glindzicz M. Spectrum of GJB2 mutations causing deafness in the British Bangladeshi population. Clinical Otolaryngology. 2008;33:313–8. doi: 10.1111/j.1749-4486.2008.01754.x. PubMed PMID: 18983339. [PubMed: 18983339]

89. Carrasquillo MM, Zlotogora J, Bargés S, Chakravarti A. Two different connexin 26 mutations in an inbred kindred segregating non-syndromic recessive deafness: Implications for genetic studies in isolated populations. Human Molecular Genetics. 1997;6:2163–72. doi: 10.1093/hmg/6.12.2163. PubMed PMID: 9328482. [PubMed: 9328482]

90. Beltramello M, Piazza V, Bukauskas FF, Pozzan T, Mammano F. Impaired permeability to Ins(1,4,5)P3 in a mutant connexin underlies recessive hereditary deafness. Nature cell biology. 2005;7:63–9. doi: 10.1038/nclb015. PubMed PMID: 15592461. [PubMed: 15592461]

91. Kenna MA, Wu BL, Cotanche DA, Kor BR, Rehm HL. Connexin 26 studies in patients with sensorineural hearing loss. Archives of Otolaryngology--Head and Neck Surgery. 2001;127:1037–42. PubMed PMID: 11556849. [PubMed: 11556849]

92. Wang HL, Chang WT, Li AH, Yeh TH, Wu CY, Chen MS, et al. Functional analysis of connexin-26 mutants associated with hereditary recessive deafness. Journal of Neurochemistry. 2003;84:735–42. doi: 10.1046/j.1471-4159.2003.01555.x. PubMed PMID: 12562518. [PubMed: 12562518]

93. Ambrosi C, Boassa D, Pranskevich J, Smock A, Oshima A, Xu J, et al. Analysis of four connexin26 mutant gap junctions and hemichannels reveals variations in hexamer stability. Biophysical journal. 2010;98:1809–19. doi: 10.1016/j.bpj.2010.01.019. PubMed PMID: 20441744. [PubMed: 20441744]

94. Thönnissen E, Rabionet R, Arbonès ML, Estivill X, Willecke K, Ott T. Human connexin26 (GJB2) deafness mutations affect the function of gap junction channels at different levels of protein expression. Human Genetics. 2002;111:190–7. doi: 10.1007/s00439-002-0750-2. PubMed PMID: 12189493. [PubMed: 12189493]

95. Cryns K, Orzan E, Murgia A, Huygen PLM, Moreno F, del Castillo I, et al. A genotype-phenotype correlation for GJB2 (connexin 26) deafness. Journal of medical genetics. 2004;41:147–54. doi: 10.1136/jmg.2003.013896. PubMed PMID: 14985372. [PubMed: 14985372]

96. Mhaske PV, Levit Na, Li L, Wang H-Z, Lee JR, Shuja Z, et al. The human Cx26-D50A and Cx26-A88V mutations causing keratitis-ichthyosis-deafness syndrome display increased hemichannel activity. American journal of physiology Cell physiology. 2013;304:C1150–8. doi: 10.1152/ajpcell.00374.2012. PubMed PMID: 23447037. [PubMed: 23447037]

97. Meigh L, Hussain N, Mulkey DK, Dale N. Connexin26 hemichannels with a mutation that causes KID syndrome in humans lack sensitivity to CO2. eLife. 2014;3:e04249. doi: 10.7554/eLife.04249. PubMed PMID: 25422938. [PubMed: 25422938]

98. Bicego M, Beltramello M, Melchionda S, Carella M, Piazza V, Zelante L, et al. Pathogenetic role of the deafness-related M34T mutation of Cx26. Human Molecular Genetics. 2006;15:2569–87. doi: 10.1093/hmg/ddl184. PubMed PMID: 16849369. [PubMed: 16849369]

99. Posukh O, Pallares-Ruiz N, Tadinova V, Osipova L, Claustres M, Roux A-F. First molecular screening of deafness in the Altai Republic population. BMC medical genetics. 2005;6:12. doi: 10.1186/1471-2350-6-12. PubMed PMID: 15790391. [PubMed: 15790391]

100. Löfler J, Nekahn D, Hirst-Statdmann a, Günther B, Menzel HJ, Utermann G, et al. Sensorineural hearing loss and the incidence of Cx26 mutations in Austria. European journal of human genetics : EJHG. 2001;9:226–30. doi: 10.1038/sj.ejhg.5200607. PubMed PMID: 11313763. [PubMed: 11313763]
101. Mani RS, Ganapathy A, Jalvi R, Srikumari Srisailapathy CR, Malhotra V, Chadha S, et al. Functional consequences of novel connexin 26 mutations associated with hereditary hearing loss. European journal of human genetics : EJHG. 2009;17:502–9. doi: 10.1038/ejhg.2008.179. PubMed PMID: 18941476. [PubMed: 18941476]

102. Yong-Yi Y, Pu D, Fei Y, Xi-Hui Z, Hui-Jun Y, Dong-Yi H, et al. GJB2 mutation spectrum in Inner Mongolia and its comparison with other Asian populations. Journal of Otology. 2007;2:81–91.

103. Meşe G, Londín E, Mui R, Brink PR, White TW. Altered gating properties of functional Cx26 mutants associated with recessive non-syndromic hearing loss. Human genetics. 2004;115:191–9. doi: 10.1007/s00439-004-1142-6. PubMed PMID: 15241677. [PubMed: 15241677]

104. Marlin S, Garabédian EN, Roger G, Moatti L, Matha N, Lewin P, et al. Connexin 26 gene mutations in congenitally deaf children: pitfalls for genetic counseling. Archives of otolaryngology--head & neck surgery. 2001;127:927–33. PubMed PMID: 11493200. [PubMed: 11493200]

105. Man YKS, Trolove C, Tattersall D, Thomas AC, Papakonstantinopoulou A, Patel D, et al. A deafness-associated mutant human connexin 26 improves the epithelial barrier in vitro. Journal of Membrane Biology. 2007;218:29–37. doi: 10.1007/s00232-007-9025-0. PubMed PMID: 17581693. [PubMed: 17581693]

106. Brobby GW, Muller-Myhsok B. Connexin 26 R143W Mutation Associated with Recessive Nonsyndromic Sensorineural Deafness in Africa. The New England Journal of Medicine. 1998;338:548–50. doi: 10.1056/NEJM199802193380813.

107. Zheng J, Ying Z, Cai Z, Sun D, He Z, Gao Y, et al. GJB2 mutation spectrum and genotype-phenotype correlation in 1067 Han Chinese subjects with non-syndromic hearing loss. PLoS ONE. 2015;10:e0128691. doi: 10.1371/journal.pone.0128691. PubMed PMID: 26043044. [PubMed: 26043044]

108. Gualandi F, Ravani A, Berto A, Sensi A, Trabaneli C, Falciano F, et al. Exploring the Clinical and Epidemiological Complexity of GJB2 -Linked Deafness. American journal of medical genetics. 2002;45:38–45. doi: 10.1002/ajmg.10621.

109. Santos RLP, Wajid M, Pham TL, Hussan J, Ali G, Ahmad W, et al. Low prevalence of Connexin 26 (GJB2) variants in Pakistani families with autosomal recessive non-syndromic hearing impairment. Clinical Genetics. 2005;67:61–8. doi: 10.1111/j.1399-0004.2005.00379.x. PubMed PMID: 15617550.

110. Primignani P, Castorina P, Sironi F, Curcio C, Ambrosetti U, Coviello DA. A novel dominant missense mutation--D179N--in the GJB2 gene (Connexin 26) associated with non-syndromic hearing loss. Clinical genetics. 2003;63:516–21. doi: 079 [pii]. PubMed PMID: 12786758. [PubMed: 12786758]

111. Su C-C, Li S-Y, Su M-C, Chen W-C, Yang J-J. Mutation R184Q of connexin 26 in hearing loss patients has a dominant-negative effect on connexin 26 and connexin 30. European journal of human genetics : EJHG. 2010;18:1061–4. doi: 10.1038/ejhg.2010.50. PubMed PMID: 20442751.

112. de Zwart-Storm Ea, van Geel M, van Neer PaFa, Steijlen PM, Martin PE, van Steensel MaM. A novel missense mutation in the second extracellular domain of GJB2, p.Ser183Phe, causes a syndrome of focal palmoplantar keratoderma with deafness. The American journal of pathology. 2008;173:1113–9. doi: 10.2353/ajpath.2008.080049. PubMed PMID: 18787097. [PubMed: 18787097]

113. Bai-Lin Wu P, Lindeman Neal, Lip Va. Effectiveness of sequencing connexin 26 (GJB2) in cases of familial or sporadic childhood deafness referred for molecular diagnostic testing. Genet Med 2002;4(4):279–288. 2002;4:279–288. doi: 10.109700125817-20020700-00006. PubMed PMID: 12172394. [PubMed: 12172394]

114. Hamelmann C, Amedofu G, Albrecht K, Muntau B, Gelhaus A. Pattern of connexin 26 (GJB2) mutations causing sensorineural hearing impairment in Ghana. Hum Mutat. 2001;18:84–5.

115. Ambrosi C, Boassa D, Pranskevich J, Smock A, Oshima A, Xu J, et al. Analysis of trafficking, stability and function of human connexin 26 gap junction channels ... Supplemental Information. PloS one. 2013:98:e70916.
116. Meşe G, Valiunas V, Brink PR, White TW. Connexin26 deafness associated mutations show altered permeability to large cationic molecules. American journal of physiology Cell physiology. 2008;295:C966–74. doi: 10.1152/ajpcell.00008.2008. PubMed PMID: 18684989. [PubMed: 18684989]

117. Han SH, Park HJ, Kang EJ, Ryu JS, Lee A, Yang YH, et al. Carrier frequency of GJB2 (connexin-26) mutations causing inherited deafness in the Korean population. Journal of Human Genetics. 2008;53:1022–8. doi: 10.1007/s10038-008-0342-7. PubMed PMID: 19043807. [PubMed: 19043807]

118. Jones DE, Lund AM, Ghandehari H, Facelli JC. Molecular dynamics simulations in drug delivery research: Calcium chelation of G3.5 PAMAM dendrimers. Cogent Chemistry. 2016;2:1229830. doi: 10.1080/23312009.2016.1229830. [PubMed: 29177183]

119. Wen J, Scoles DR, Facelli JC. Effects of the enlargement of polyglutamine segments on the structure and folding of ataxin-2 and ataxin-3 proteins. Journal of Biomolecular Structure and Dynamics. 2017;35:504–19. doi: 10.1080/07391102.2016.1152199. PubMed PMID: 26861241. [PubMed: 26861241]
Highlights

- In this paper we were able to spatially associate the 3D positions of the identified calcium binding sites within the framework of this work with reported pathogenic variants in the CJB2 gene. This study presents a first step on finding associations between molecular features and pathological variants of the Cx26 hemichannel.
Figure 1.
Schematic Representation of the Cx26 structures. A- Gap Junction channel. Each connexon shown in different color. B- Connexon structure. Each connxin has a different color. C- Connexin structure and its domains Transmembrane Segments TM1 (Yellow), TM2 (Violet), TM3 (Blue), TM4 (Light Blue); Extra-cellular Loops E1 (Green), E2 (Black); Intra-cellular C-terminal CT (Orange); Intra-cellular Loop CL (Pink), and Intra Pore Segment NTH (Red).
Figure 2.
RMSD calculations for the three of the systems considered in this study. Cases: A) $CA = 0$ (green), B) $CA = 0.04$ (red) and $CA = 0.1$ (black).
Figure 3.
RMSF of each connexin residue calculated over the simulation run. The six connexins corresponding to each case are depicted in different colors and over imposed. A) CA-0.1 case, B) CA-0.04 case and C) CA-0 case. On the top, each Cx26 domain is indicated.
Figure 4.
Electron Density profiles. A) System CA–0.1. The POPC distribution is in red, the protein distribution in black, and the water distribution in green B) Calcium EDP for the CA–0.04 (blue) and CA–0.1 (green) cases. Z=0 corresponds to the center of the membrane, the region that corresponds to the extra-cellular domains of the connexon, is located between −20 and −60 Å and the intra-cellular one is between 20 and 60 Å.
Figure 5.
Time evolution of the R1 and R2 distances: R1 and R2 are the distances between Ca$^{2+}$ and the two carboxylic O atoms in lateral chain of ASP50. The binding distance is around 2.35Å. Inset: Schematic graph of the binding interaction between Ca$^{2+}$ and ASP50. Both curves are superimposed.
Figure 6.
Time evolution of the distances between Ca$^{2+}$ and oxygen atoms in different amino acids. A), C) and E) distances with two carboxylic O atoms in the lateral chain of GLU42 (red and black), GLU47 (green and blue) and GLY45 (orange). B), D) and F) show a schematic representation of the corresponding arrangements, associated with the side figure.
Figure 7.
Sequence of Cx26 annotated with the position for which pathogenic variants reported in ClinVar and calcium binding sites have been encountered in this study. Residues highlighted in blue, orange and green correspond to those for which pathogenic variants have been reported in ClinVar, calcium binding sites found in this study and those that meet both criteria, respectively.
Figure 8:  
Relative spatial positions of the sequences EKKR(104) in blue and EFKDIEE (120) in red.  
In the first sequence pathogenic mutations have been reported at GLU101, LYS103 and ARG104, whereas in the second one the positions GLU114, ASP117, GLU119 and GLU120 have been identified as calcium binding sites.
Figure 9.
Schematic representation of the connexin. The amino acids involved in calcium specific interaction sites were highlighted in red, the ones found with the first initial condition and those observed after adding eight Ca$^{2+}$ inside the pore are in green.
### Table 1.
Summary of the four simulated systems considered in this study.

| System name | N of atoms  | N\(_0^\circ\) of Ca\(_{2+}\) | N\(_0^\circ\) of Na\(^+\) | N\(_0^\circ\) of Cl\(^-\) | Run time |
|-------------|-------------|----------------------------|--------------------------|--------------------------|----------|
| CA-0        | 229,030     | 0                          | 150                      | 204                      | 500 ns   |
| CA-0.04     | 229,138     | 36                         | 150                      | 276                      | 500 ns   |
| CA-0.1      | 229,285     | 85                         | 150                      | 374                      | 500 ns   |
| i-CA-0.1    | 229,285     | 85                         | 150                      | 374                      | 500 ns   |

& Average run times are 25 ns per day using 120 cores for systems with 164,000 sites.
| Sequences                  | Mutation reported in ClinVar | Ca+2 binding residues found in this work | GJC Function | HCs Function | Deafness Phenotype               |
|----------------------------|-------------------------------|------------------------------------------|--------------|--------------|----------------------------------|
| GVNKHSS(17)                | G12R (+) [65, 66]             | VAL226                                   | (-)          | (+)          | S, Mild, Severe, KID/EKV         |
| VLF(29)                    | V27I [67]                    | NONE                                     | Normal       | Normal       | NS, HL and Normal               |
| RIMILV(37)                 | V37I [68]                    | ASP2                                     | (-)          | (-)          | NS, Mild-Moderate, Severe        |
| WGD(46)                    | W44C W44S D46E [24, 69–75]   | GLU42                                    | (-)          | n.d.         | NS, Severe to Profound, HL, Moderate, Severe |
|                            | G45E [76–81]                 |                                          |              |              |                                  |
| NTLQPG(59)                 | G59V [82, 83]                | ASP2 GLU42 GLU47 ASP50                   | n.d.         | (-)          | NS, Profound                     |
| YDH(66)                    | D66H [70–72]                 | NONE                                     | n.d.         | n.d.         | Multilating keratoderma (No deafness reported) |
| ISHIRLWALQ(80)             | R75Q R75W [70, 71, 84–86]    | ASP2 GLU42 GLU47 ASP50                   | (-)          | (-)          | S, Severe to Profound, PPK       |
|                            | W77R [87–89]                 |                                          |              |              |                                  |
| FVSTPALL(90)               | V84L [87, 90–93]             | ASP2                                     | n.d.         | NS          | Profound                         |
|                            | T86R A88S L90P [73, 94, 95]  |                                          | (-)          | (-)          | NS, Profound, Moderate to Profound, Mild to Moderate |
|                            | A88V [86, 96, 97]            |                                          | n.d.         | (+)          | S, Severe to Profound, KID       |
| MHV(95)                    | n.d.                         | NONE                                     |              |              |                                  |
| EKRR(104)                  | n.d.                         | GLU114 ASP117 GLU119 GLU120              | n.d.         | n.d.         | NS                               |
| Punctual: E114G R127H      | E114G R127H [67, 82, 83, 92, 98–100] | GLU114 ASP117 GLU119 GLU121 | (-)          | (-)          | NS, Severe to Profound, Profound |
| IEE(120)                   | De1E120 [24, 87, 101]        | OVERLAP WITH GLU114 ASP117 GLU119 GLU120 | (-)          | n.d.         | NS, Severe to Profound           |
| TQKVRIEG(130)              | G130A [102]                  | GLU114 ASP117 GLU119 GLU120 VAL226      | n.d.         | n.d.         | NS, HL                           |
| FRVIFEA(148)               | R143Q [70, 71, 100, 103, 104] | NONE                                     | (-)          | n.d.         | NS, Profound                     |
|                            | R143W [82, 92, 103, 105, 106] |                                          | (-)          | (-)          | NS, Profound                     |
| YYF(154)                   | V153I [64]                   | ASP159                                   | n.d.         | n.d.         | NS, HL, NS (No deafness reported) |
| YDG(160)                   | G160S [107]                  | OVERLAP WITH ASP159                      | n.d.         | n.d.         | S, HL, KID                       |
|                            | D159V [108]                  |                                          |              |              |                                  |
| RLVKC(169)                 | R165W [109]                  | NONE                                     | (-)          | n.d.         | NS, HL, Severe to Profound       |
| VDC(180)                   | D179N [110]                  | NONE                                     | (-)          | n.d.         | NS, HL, Severe to Profound       |
| Sequences | Mutation reported in ClinVar | Ca\(^{+2}\) binding residues found in this work | GJC Function | HCs Function | Deafness Phenotype |
|-----------|-----------------------------|-----------------------------------------------|--------------|--------------|-------------------|
| SRP(185)  | R184P R184Q [64, 111]       | NONE                                          | (-)          | n.d.         | NS, HL, Severe to Profound |
|           | S183F [112]                 |                                               | (-)          | n.d.         | S, High Frequency HL, PPK |
| FTVFMIA(197) | M195T A197S [113–116]       | NONE                                          | (-)          | n.d.         | NS, HL, Moderate, Profound |
| CIL(204)  | C202F [62]                  | NONE                                          | n.d.         | (-)          | NS, Mild to Moderate |
|           | I203T [117]                 |                                               | (-)          | (-)          | NS, HL, Profound |
| LLI(215)  | L214P [114]                 | NONE                                          | n.d.         | n.d.         | NS, HL |

*Residues in **bold** have pathogenic mutations reported in ClinVar. The number between parentheses corresponds to the sequence number of the last amino acid listed.

\(^{d}\)Ca\(^{+2}\) binding residues found in the MD simulations that have spatial proximity to the sequence with reported mutations.

S. Syndromic; NS. Non-syndromic; HL. Hearing-loss; KID. Keratitis-ichthyosis-deafness; n.d. No-data available.

\(^{(*)}\) Generate gain of HC function when they are expressed with wild type Cx26 or Cx43[66]